Total U.S. pharmaceutical and biotech revenues for products 5 years after launch from 2007 to 2017 (in billion U.S. dollars)

Total U.S. pharma and biotech product sales 5 years after launch 2007-2017 This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.
Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Show more
Loading statistic...
Revenue in billion U.S. dollars
20074.3
20085.6
20095.4
201012.5
201111.9
2012*13.9
201312.3
201419.8
201523.7
201611
2017**31.6
Revenue in billion U.S. dollars
20074.3
20085.6
20095.4
201012.5
201111.9
2012*13.9
201312.3
201419.8
201523.7
201611
2017**31.6
Download Settings Share
Chart type
Datalabels
Share on Social Media
HTML code to embed chart as PNG (FAQ)
Download started
Please be patient - this may take a moment
Description Source More information
This statistic depicts the total pharmaceutical and biotech product revenues in the United States of products five years after launch, from 2007 to 2017. In 2010, product revenues in the U.S. totaled 12.5 billion U.S. dollars for products launched 5 years before.
Pharma and biotech products

Newer pharmaceutical and biotechnology products have generated increasingly large amounts of revenues after five years of launch. In 2008, revenues were at 5.6 billion U.S. dollars but had skyrocketed to some 31 billion U.S. dollars in 2017. The average cost of developing a new pharmaceutical or biotech entity has increased from 451 million U.S. dollars in 1991 to some 1.5 billion U.S. dollars in the 2010s. Many companies that had once focused primarily on pharmaceuticals have begun to integrate biotechnology in their research, which has minimized the separation between the two industries.

Pharmaceuticals are most commonly manufactured through chemical synthesis processes while biotechnology pharmaceuticals are products created within living organisms such as bacteria and yeast. Recently, biological drugs have become the most prominent products in the medicinal industry. For example, Humira, otherwise known as adalimumab, was approved in the United States by the Food and Drug Administration (FDA) in 2008. Humira is marketed by AbbVie and is used as an anti-inflammatory drug. It has since become one of the largest grossing medical products in the world, generating about 16 billion U.S. dollars in 2015. In the United States, Humira generated 13.6 billion U.S. dollars in revenue in 2016. Expenditure on biologics is expected to increase to 221 billion U.S. dollars globally by 2017.
Show more
Release date
December 2017
Region
United States
Survey time period
as of November 2017
Supplementary notes
* Values until 2012 were assembled from previous editions of the report.
** Potential total for 2017.

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Biotech industry"

  • Overview U.S. and Europe
The most important statistics
  • Global companies
  • U.S. companies
  • Top U.S. regions
The most important statistics
  • Products/R&D
  • Biotech in agriculture

Related Studies: Available to Download in PDF or PPTX Format

Biotech industry

All Information
in one Presentation

Biotech industry

Everything On "Biotech industry" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar